Actively Recruiting

Age: 18Years +
All Genders
ID06629194

Validation of Scoring Systems for Differentiating Intestinal Tuberculosis from Crohn's Disease Using Clinical, Endoscopic, and Interferon-gamma Releasing Assay in Asian Population

Led by Mahidol University · Updated on 2024-10-08

84

Participants Needed

2

Research Sites

8 weeks

Total Duration

On this page

Sponsors

M

Mahidol University

Lead Sponsor

K

Korean Association for the Study of Intestinal Diseases

Collaborating Sponsor

AI-Summary

What this Trial Is About

Differentiating Crohn's disease (CD) from intestinal tuberculosis (ITB) is challenging because current diagnostic tests have low sensitivity. This research aims to validate scoring models that combine clinical, endoscopic, and serological data, including interferon gamma-releasing assay (IGRA) results, to improve diagnosis accuracy. The study focuses on models suitable for resource-limited settings, as advanced imaging and pathology may not be widely available. Accurate distinction is important to avoid incorrect treatment, which can lead to complications or severe relapse. Participants diagnosed with either Crohn's disease or intestinal tuberculosis will be included. Diagnosis of CD is based on clinical, endoscopic, pathological, or radiological findings confirmed by treatment response. ITB diagnosis requires specific pathological or microbiological evidence or a positive response to anti-tuberculous therapy (ATT). All patients suspected of CD or ITB will undergo IGRA blood testing. The study evaluates the accuracy of diagnostic models, including those integrating clinical, endoscopic, and serological findings. During the study, patients will undergo colonoscopy and have tissue samples tested for mycobacterial infections using stains, PCR, and cultures. Researchers will assess the accuracy of scoring models using colonoscopy results after four weeks. Participants will be monitored for clinical and endoscopic responses to their respective treatments—either Crohn's disease therapies or ATT. This observational study will help validate diagnostic tools to better distinguish between CD and ITB and improve patient care.

CONDITIONS

Brief Title

Validation of Scoring Systems for Differentiating Intestinal Tuberculosis from Crohn's Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients ages 18 years or older
  • Undergoing colonoscopy with ileal or colonic ulcers found
  • Have ileal and/or colonic tissue sent for mycobacterial tests including stain for AFB, PCR, and culture
  • Diagnosed with either intestinal tuberculosis or Crohn's disease
  • For intestinal tuberculosis diagnosis, must have one of the following: caseating granuloma on pathology, acid-fast bacilli on pathology, PCR positive for Mycobacterium tuberculosis, tissue culture growing Mycobacterium tuberculosis, or negative results but clinical and endoscopic response to anti-tuberculous therapy
  • For Crohn's disease diagnosis, based on clinical, endoscopic, pathological, and/or radiological findings confirmed by response to Crohn's disease treatment
Not Eligible

You will not qualify if you...

  • Patients with ileal or colonic ulcers caused by diseases other than Crohn's disease or intestinal tuberculosis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 4 weeks

Participants undergo diagnostic tests including colonoscopy with tissue sampling and interferon gamma releasing assay (IGRA) to differentiate between Crohn's disease and intestinal tuberculosis.

1 to 2 visits depending on diagnostic procedures

Long-term Monitoring

Duration - Variable duration following diagnosis

Participants diagnosed with either Crohn's disease or intestinal tuberculosis are observed to confirm diagnosis based on clinical and endoscopic response to their respective treatments.

Visits scheduled according to clinical follow-up needs

Trial Site Locations

Total: 2 locations

1

Assoc. Prof. Julajak Limsrivilai, MD

Bangkok Noi, Bangkok, Thailand, 10700

Actively Recruiting

2

Gastroenterology division, Faculty of Medicine, Siriraj Hospital, Mahidol University

Bangkok, Thailand, 10700

Not Yet Recruiting

Loading map...

Research Team

J

Julajak Limsrivilai

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A 15-Year Cohort Study to Analyze Risk Factors for Mortality...

Intestinal Tuberculosis

Actively Recruiting

1 location

Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the...

Crohn Disease

Actively Recruiting

2 locations

A Master Protocol for Phase 2, Randomized, Controlled Studie...

Colitis, Ulcerative

Actively Recruiting

72 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here